0001144204-19-044792.txt : 20190916
0001144204-19-044792.hdr.sgml : 20190916
20190916204758
ACCESSION NUMBER: 0001144204-19-044792
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20190329
FILED AS OF DATE: 20190916
DATE AS OF CHANGE: 20190916
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: SQUINTO STEPHEN P
CENTRAL INDEX KEY: 0001231954
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39044
FILM NUMBER: 191095863
MAIL ADDRESS:
STREET 1: C/O ALEXION PHARMACEUTICALS INC
STREET 2: 352 KNOTTER DRIVE
CITY: CHESHIRE
STATE: CT
ZIP: 06410
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: SpringWorks Therapeutics, Inc.
CENTRAL INDEX KEY: 0001773427
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 100 WASHINGTON BOULEVARD
CITY: STAMFORD
STATE: CT
ZIP: 06902
BUSINESS PHONE: 203-883-9490
MAIL ADDRESS:
STREET 1: 100 WASHINGTON BOULEVARD
CITY: STAMFORD
STATE: CT
ZIP: 06902
4
1
tv529540_form4.xml
FORM 4
X0306
4
2019-03-29
0
0001773427
SpringWorks Therapeutics, Inc.
SWTX
0001231954
SQUINTO STEPHEN P
C/O SPRINGWORKS THERAPEUTICS, INC.
100 WASHINGTON BLVD.
STAMFORD
CT
06902
1
0
1
0
Stock Option (Right to Buy)
18.00
2019-09-12
4
A
0
29983
0
A
2029-09-12
Common Stock
29983
29983
D
Series A Convertible Preferred Stock
2019-03-29
4
A
0
40000000
A
Common Stock
6078103
6078103
I
See footnote
Series B Convertible Preferred Stock
2019-03-29
4
A
0
6931142
A
Common Stock
1053204
1053204
I
See footnote
This option shall vest in equal monthly installments over the period of thirty six (36) months following September 12, 2019, subject to continued service to the Issuer on each vesting date.
On March 29, 2019, pursuant to a corporate reorganization, all of the equity interests in SpringWorks Therapeutics, LLC were exchanged for the same number and class of newly issued securities of SpringWorks Therapeutics, Inc. Pursuant to the reorganization, OrbiMed Capital GP VI LLC ("GP VI") received 40,000,000 shares of Series A Convertible Preferred Stock of the Issuer. Each share of Series A Convertible Preferred Stock is convertible into shares of the Issuer's Common Stock on a 6.5810:1 basis. Immediately prior to the closing of the Issuer's initial public offering, all shares of Series A Convertible Preferred Stock will convert into shares of Common Stock of the Issuer. The Series A Convertible Preferred Stock has no expiration date.
Shares held by GP VI. GP VI is the general partner of OrbiMed Private Investments VI, LP ("OrbiMed VI"). OrbiMed Advisors LLC ("Advisors") is the managing member of GP VI. By virtue of such relationship, GP VI and Advisors may be deemed to have voting and investment power with respect to the shares held by OrbiMed VI and as a result may be deemed to have beneficial ownership of such shares. The reporting person is an Executive Partner at Advisors. This report shall not be deemed an admission that the reporting person is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.
On March 29, 2019, GP VI acquired 6,931,142 shares of Series B Convertible Preferred Stock of the Issuer. Each share of Series B Convertible Preferred Stock is convertible into shares of the Issuer's Common Stock on a 6.5810:1 basis. Immediately prior to the closing of the Issuer's initial public offering, all shares of Series B Convertible Preferred Stock will convert into shares of Common Stock of the Issuer. The Series B Convertible Preferred Stock has no expiration date.
/s/ Michael V. Greco as Attorney-in-Fact
2019-09-16